Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab

Exclusion criteria

• . Unable to commit to the scheduled visits as required by the protocol, or unable to commit to undergoing protocol guided reductions in asthma therapy, as directed by the Investigator.
• . Clinically important pulmonary disease other than asthma (e.g., active lung infection, chronic obstructive pulmonary disease \[COPD\], bronchiectasis, pulmonary fibrosis, cystic fibrosis), or ever been diagnosed with pulmonary or systemic disease, other than asthma, that is associated with elevated peripheral eosinophil counts (e.g., allergic bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome).
• . Current smokers at Visit 1 are not allowed. Former smokers with smoking history ≥ 10 pack-years at Visit 1 are not allowed; Former smokers with a smoking history of \<10 pack years must have stopped for at least 6 months to be eligible.
• . History of alcohol or drug abuse within 12 months prior to Visit 1(Week -1 to Week 0).
• . A helminth parasitic infection diagnosed within 24 weeks prior to Visit 1(Week -1 to Week 0) that has not been treated with, or has failed to respond to, standard of care therapy.
• . History of anaphylaxis to any biologic therapy.
• . Known history of allergy or reaction to any component of the study treatment formulation.
• . Respiratory exacerbation requiring use of Systemic corticosteroids (SCS) or acute upper/lower respiratory infection that required antibiotics or antiviral medication within 30 days prior to Visit 1(Week -1 to Week 0). An extension of the screening period up to 3 months is allowed to ensure that a patient recovering from any repiratory exacerbation or acute upper/lower respiratory infection can be included.